Back to search results
Rahul Aggarwal
4.9 out of 5 (294)
Rahul Aggarwal

Rahul Aggarwal, MD

Genitourinary Medical Oncology

Cancer Clinical Trials and Investigational Treatments Center
1825 Fourth St., Fifth Floor,
San Francisco, CA 94158
+3 more locations
(415) 476-4616
4.9 out of 5 (294)
Virtual visits available
4.9 out of 5 (294)
Virtual visits available
Cancer Clinical Trials and Investigational Treatments Center
1825 Fourth St., Fifth Floor,
San Francisco, CA 94158
+3 more locations
(415) 476-4616

Dr. Rahul Aggarwal is a specialist in cancers of the genital and urinary organs. He cares for patients at the UCSF Helen Diller Family Comprehensive Cancer Center. He also serves as director of the UCSF STAND (Supportive Therapy in Androgen Deprivation) Clinic, which provides comprehensive care to men who are receiving androgen deprivation therapy, hormone therapy for prostate cancer.

As a member of the Developmental Therapeutics Genitourinary Cancer Program, Aggarwal enrolls patients with advanced solid tumor malignancies into early-phase clinical trials of novel targeted treatments. His research focuses on developing hormonal treatment strategies that reduce the toxicity of androgen deprivation therapy for men with advanced prostate cancer. He is also interested in developing new molecular imaging techniques that will help predict how advanced solid tumors will respond to treatment.

Aggarwal earned his medical degree from the Northwestern University Feinberg School of Medicine. At UCSF, he completed an internship and residency in internal medicine, followed by a clinical fellowship in hematology and oncology.

Aggarwal has also been a research fellow in developmental therapeutics at Genentech. He is a member of the American Society of Clinical Oncology (ASCO) and recipient of the ASCO/Conquer Cancer Foundation Young Investigator Award.

  • Board Certifications

    American Board of Internal Medicine, Hematology, 2014

    American Board of Internal Medicine, Medical Oncology, 2013

  • Fellowships

    UCSF, Hematology - Oncology, 2013

  • Internship

    UCSF, Internal Medicine, 2007

  • Degree

    Northwestern University, Feinberg School of Medicine, 2006

It's an honor to help take care of people with cancer, and I strive each and every day to improve outcomes for our patients.

Conditions I specialize in

Where I see patients (4)

    My reviews

    4.9

    Overall Experience
    294 Ratings
    About our process
    Jun 21, 2025
    The care provider provided excellent service on the video appointment. He provided detailed information and fully explained the subjects we discussed. Additionally, he provided In depth responses to questions I had.
    Jun 18, 2025
    Dr. Aggarwal is a great example of UCSF care and compassion.
    May 20, 2025
    Excellent doctor, excellent visit, thank you for the help.
    May 14, 2025
    Dr Agarwal is amazing!
    Apr 13, 2025
    Dr Aggarwal was prepared for our meeting by knowing my medical history. He described a trial that I may be able to join in a way that I could easily understand. He was informative, empathic, and professional.
    Apr 09, 2025
    Pretty much upfront about the pros & cons of treatment possibilities.
    Mar 27, 2025
    Dr. Aggarwal was very professional and thorough. He listened well, stayed engaged and answered my questions completely. Great experience.
    Mar 10, 2025
    Awesome
    Mar 06, 2025
    Dr. Aggarwal is a class act. Always engaged and genuine.
    Feb 26, 2025
    I had good experience of the appointment
    Feb 25, 2025
    He came with high marks in terms of references. Thus far I can certainly see why!
    Feb 20, 2025
    Great conversation. Thank you!
    Feb 04, 2025
    I felt very content after I spoke with the doctor.
    Jan 25, 2025
    Dr. Aggarwal is the consummate professional.
    Jan 18, 2025
    Doctor was very willing to take his time to explain everything
    Nov 29, 2024
    Caring, professional, respectful, knowledgeable, outstanding care.
    Nov 26, 2024
    Always a pleasure to speak with Dr. Aggerwal.
    Aug 27, 2024
    Excellent meeting.
    Aug 14, 2024
    he is an excellent doctor
    Jul 18, 2024
    It continues to be a very good method of communication with my caregivers.
    Jul 12, 2024
    Rahul was excellent in his explanation of possible treatment options and clearly answering my questions.
    Jun 21, 2024
    I listen to and follow the instructions and treatment recommendations provided by Dr. Aggarwal and I'm very satisfied with the status and outcomes of the treatment prescribed to date.
    Jun 15, 2024
    I am fortunate to be his care
    May 16, 2024
    I consider myself to be extremely fortunate to have Dr Aggarwal and his extraordinary team at my side!
    May 15, 2024
    Rahul is the best!
    May 15, 2024
    I have sent many people/friends to UCSF for treatment. All are doing very well. It's a World Class facility.
    May 03, 2024
    Dr Aggarwal is the finest physician I have ever had in my life.
    Mar 28, 2024
    Great
    Mar 21, 2024
    Outstanding experience in every aspect
    Mar 15, 2024
    Dr continues to demonstrate the highest level of knowledge, compassion and communication skills.
    Mar 07, 2024
    Dr. Aggarwal is wonderful
    Dec 01, 2023
    The doctor that I deal with Was very very helpful and I hope to continue working with you guys
    Nov 27, 2023
    Very professional
    Nov 08, 2023
    I have a good friend ready to get treated by UCSF Urology Group right now - he is receiving World Class care and advice.
    Oct 24, 2023
    Super
    Oct 19, 2023
    The Doctor was wonderful. Easy to follow and answered all of our question.
    Oct 13, 2023
    I have the best team of doctors
    Sep 28, 2023
    I appreciate the respect and care Dr. Aggarwall extends to us
    Sep 27, 2023
    UCSF is the best, thank you
    Sep 25, 2023
    The doctor was such a wonderful listener.
    Sep 22, 2023
    Fantastic resource
    Sep 20, 2023
    We always feel like we are getting special care with Dr Aggarwal
    Sep 13, 2023
    My admiration for the doctor Aggarwal and his team
    Aug 30, 2023
    I love my care
    Aug 23, 2023
    Great experience
    Aug 23, 2023
    Dr. Aggarwal is terrific!!!
    Aug 18, 2023
    Always good

    Selected research

    See all research
    Decorative Caduceus

    Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

    rPFS is defined as the amount of time from the initiation of study therapy and the day of first documented radiographic disease progression per RECIST version 1.1 and PCWG3 criteria. The proportion of patients without radiographic...

    Recruiting

    Decorative Caduceus

    177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer

    Treatment emergent adverse events will be classified according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Adverse events and clinically significant laboratory abnormalities (meeting Grade 3, 4, or 5 cr...

    Recruiting

    Decorative Caduceus

    Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

    Recruiting

    Decorative Caduceus

    Study of SX-682 Plus Enzalutamide in Men With Abiraterone-Resistant Metastatic Castration Resis...

    A composite endpoint defined as 1) iRECIST iCR or iPR, 2) PSA50 or 3) stable disease by iRECIST and PCWG3 bone scan criteria for at least 6 months

    Recruiting

    Decorative Caduceus

    A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastati...

    To compare the PFS between treatment arms. PFS is defined as the time (month) interval between date of randomization and date of radiographic disease progression or death for those without prior evidence of progression, as assesse...

    Recruiting

    Decorative Caduceus

    Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With So...

    On overall response will be reported as a percentage of participants with a complete response (CR) or partial response (PR) as measured by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Recruiting

    Decorative Caduceus

    Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

    To assess the safety and tolerability of MOMA-313 given as a single-agent or in combination with olaparib

    Recruiting

    Decorative Caduceus

    A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/H...

    An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-sp...

    Recruiting

    Decorative Caduceus

    A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the...

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment...

    Recruiting

    Decorative Caduceus

    64Cu-GRIP B in Patients With Advanced Malignancies

    For Cohort A, the frequency and severity of adverse events following 64Cu-GRIP B injection will be descriptively reported, using NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

    Recruiting

    Contact me

    Share